Neurosterix Closes $105 Million Series B

Addex disclosed November 11 that its 2024 spinout Neurosterix closed a $105 million Series B to advance NTX-253 toward Phase 2 schizophrenia development. This is newly closed capital, not an announced target.

Addex disclosed November 11 that its 2024 spinout Neurosterix closed a $105 million Series B to advance NTX-253 toward Phase 2 schizophrenia development. This is newly closed capital, not an announced target.